Trial reportDiabetes care2020
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease.
Trial report in Diabetes care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Pooled it
- Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.The lancet. Diabetes & endocrinology · 2024 · on this mapPooled it
- The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis.European heart journal. Cardiovascular pharmacotherapy · 2022Pooled it
- CETP Renaissance with Obicetrapib.Current atherosclerosis reports · 2026Review
- Cholesteryl Ester Transfer Protein Inhibitors: State of the Science.Current cardiology reports · 2026Review
- HDL metabolism and function in diabetes mellitus.Nature reviews. Endocrinology · 2026Review
- Nicorandil in improving angina pectoris and vascular endothelial function in elderly diabetes mellitus patients with coronary heart disease.Journal of cardiothoracic surgery · 2025Article
- High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe?International journal of molecular sciences · 2025Review
- Structure-based mechanism and inhibition of cholesteryl ester transfer protein.Current atherosclerosis reports · 2023Review
- Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?Cardiovascular research · 2022Article
- HDL as Bidirectional Lipid Vectors: Time for New Paradigms.Biomedicines · 2022Review
- Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes.Cardiovascular diabetology · 2022Observational
- Article
- HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review.International journal of molecular sciences · 2021Review
- High Density Lipoproteins and Diabetes.Cells · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 12 institutions in 7 countries.
Funding
Abstract
objectiveIncident type 2 diabetes is common among patients with recent acute coronary syndrome and is associated with an adverse prognosis. Some data suggest that cholesteryl ester transfer protein (CETP) inhibitors reduce incident type 2 diabetes. We compared the effect of treatment with the CETP inhibitor dalcetrapib or placebo on incident diabetes in patients with recent acute coronary syndrome. RESEARCH DESIGN AND
methodsIn the dal-OUTCOMES trial, 15,871 patients were randomly assigned to treatment with dalcetrapib 600 mg daily or placebo, beginning 4-12 weeks after an acute coronary syndrome. Absence of diabetes at baseline was based on medical history, no use of antihyperglycemic medication, and hemoglobin A
resultsAt baseline, 10,645 patients (67% of the trial cohort) did not have diabetes. During a median follow-up of 30 months, incident diabetes was identified in 403 of 5,326 patients (7.6%) assigned to dalcetrapib and in 516 of 5,319 (9.7%) assigned to placebo, corresponding to absolute risk reduction of 2.1%, hazard ratio of 0.77 (95% CI 0.68-0.88;
conclusionsIn patients with a recent acute coronary syndrome, incident diabetes is common and is reduced substantially by treatment with dalcetrapib.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.